Open Access
ARTICLE
HAIYING PANG1,#, FENGBO WU1,#, YU ZHANG1, NAN ZHANG2, CHUNTING WANG1, QIU LI1, GU HE1,*, PENG ZHANG3,*
1 Department of Pharmacy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China
2 State Key Laboratory of Southwestern Chinese Medicine Resources, College of Medical Technology and School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China
3 Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, 610041, China
* Corresponding Author: GU HE. Email: ; PENG ZHANG. Email:
(This article belongs to the Special Issue: Signaling Pathway Crosstalk in Malignant Tumors: Molecular Targets and Combinatorial Therapeutics)
Oncology Research https://doi.org/10.32604/or.2024.043948
Received 17 July 2023; Accepted 13 May 2024; Published online 11 June 2024
View
Download
Like
miR-122 Inhibits Hepatocarcinoma Cell Progression by Targeting LMNB2
Xiao-Na Li, Hong Yang, Tao YangTBK1 Inhibitor Exerts Antiproliferative Effect on Glioblastoma Multiforme Cells
Sarah A. Scuderi, Marika Lanza,...